Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab

Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab

Progressive multifocal leukoencephalopathy (PML) is increasingly being reported in patients undergoing immunotherapy. We report a case of progressive multifocal leukoencephalopathy after treatment with nivolumab, a PD-1 blocker that is used to restore impaired T-cell responses in patients with cance...

Full description

Bibliographic Details
Main Authors: Martin Martinot, Guido Ahle, Inesa Petrosyan, Camille Martinez, Dragos M. Gorun, Mahsa Mohseni-Zadeh, Samira Fafi-Kremer, Martine Tebacher-Alt
Format: Article
Language:English
Published: Centers for Disease Control and Prevention 2018-08-01
Series:Emerging Infectious Diseases
Subjects:
nivolumab
immune checkpoint inhibitor
progressive multifocal leukoencephalopathy
JC virus
viruses
meningtitis/encephalaitis
Online Access:https://wwwnc.cdc.gov/eid/article/24/8/18-0460_article
Description
Summary:Progressive multifocal leukoencephalopathy (PML) is increasingly being reported in patients undergoing immunotherapy. We report a case of progressive multifocal leukoencephalopathy after treatment with nivolumab, a PD-1 blocker that is used to restore impaired T-cell responses in patients with cancer and infections. Data for 4 other cases were obtained from pharmacovigilance databases.
ISSN:1080-6040
1080-6059

Similar Items